Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) is saying goodbye to its remaining global women’s health business assets in exchange for $1.38 billion.
Here’s why analysts are playing it cautiously optimistic on the struggling pharmaceutical giant.
A glimpse into OrbiMed Advisors’ recent moves in the healthcare space.
Analyst Louise Chen cheers that new Danish CEO means “good news” for Tesla investors.
How Do Biotech’s Movers and Shakers Fare Under Puravida Funds’ Healthcare-Centric Trading Strategy?
TEVA’s Brand Drug Portfolio and Pipeline Are Undervalued, Says Analyst
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) announced that the FDA has approved AUSTEDO (deutetrabenazine) tablets for the treatment of tardive dyskinesia in adults. AUSTEDO®was …
TEVA Core Challenges Aren’t Going To Fade Anytime Soon, Says Analyst
Two Pharmaceutical Companies that Have Recently Found Themselves in Hot Water Look for Relief
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) announced the launch of generic Axiron®1 (testosterone) topical solution CIII, 30 mg/1.5 mL, in the U.